Prognostic performance of thymidine kinase 1 activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with CDK4/6 and aromatase inhibitors
Baseline TKa provides prognostic information, with potential added value from repeated testing in those with high baseline levels. TKa behaves as a continuous biomarker of risk, and continuous modelling may offer more clinically informative individual risk estimation, while thresholds may retain value for specific clinical contexts. Validation in larger cohorts is warranted to support integration into routine practice.
Authors
- Maria Ekholm (ORCID: https://orcid.org/0000-0002-5553-5323)
- Ellinor Elinder (ORCID: https://orcid.org/0000-0001-8596-5327)
- Monika Umińska
- S. Howell
- Nicole L. Brown
- Karolina Larsson
- Ahmed Albu-Kareem
- Dimitrios Papantoniou
- Alexandra Backlund
- Mattias Bergqvist
- Olle Eriksson
- Amy Kavanagh
- Amy Williams
Institutions
- Linköping University (SE)
- Sahlgrenska University Hospital (SE)
- University of Manchester (GB)
- Stockholm South General Hospital (SE)
- Region Jönköpings län (SE)
- The Christie NHS Foundation Trust (GB)
- Swedish Orphan Biovitrum (Sweden) (SE)
- Landstinget i Kalmar län (SE)
- Ryhov Hospital Jönköping (SE)
- Linköping University Hospital (SE)
- University of Gothenburg (SE)
Publication Details
- Journal
- Breast Cancer Research and Treatment
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1007/s10549-025-07879-0
- Citations
- 1
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 36.44
Funders
- Linköpings Universitet